查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552895

癌症生物標記市場規模、佔有率、趨勢分析報告：按類型、生物分子、應用、技術、地區和細分市場預測，2024-2030

Cancer Biomarkers Market Size, Share & Trends Analysis Report By Type (Breast Cancer, Prostate Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, By Technology, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

癌症生物標記市場成長與趨勢

根據Grand View Research, Inc.最新報告顯示，到2030年，全球癌症生物標記市場規模預計將達到697.6億美元，預計2024年至2030年複合年成長率為12.7%。

由於針對新型癌症生物標記的藥物開發的開創性舉措，加上技術先進的伴同性診斷試劑套件的採用，預計該市場具有很高的成長潛力。提高患者對個人化醫療的認知也有望支持癌症生物標記的採用。

此外，政府積極努力開發新的癌症診斷技術也是促進市場成長的關鍵因素。例如，美國國家癌症美國(NCI) 資助了超過八個與癌症生物標記開發相關的研究領域。英國癌症研究中心、肺癌研究基金會和美國國立衛生研究院是資助生物標記研究的組織之一。

據報道，大量飲酒、吸煙、有不健康飲食習慣和久坐生活方式的人患癌症的風險比其他人高 80%。人類乳突病毒 (HPV)、 EB病毒、B型肝炎病毒和幽門螺旋桿菌等感染疾病也被研究與癌症的發生有關。

癌症生物標記市場報告亮點

  • 收益而言，到 2023 年，乳癌細分市場將佔據重要的市場佔有率，預計在預測期內複合年成長率將達到最快。
  • 其他細分市場將在 2023 年成長，這與罕見癌症研究的增加、基因組學和蛋白​​質組學的進步、胰腺癌和卵巢癌等癌症發病率的上升以及對個性化醫療的需求不斷成長有關，佔據了顯著的佔有率。
  • 以 2023 年收益佔有率計算，遺傳生物標記細分市場佔據主導地位。由於多種促進因素​​，遺傳生物標記在癌症生物標記市場中至關重要。
  • 表觀遺傳學領域是預測期內成長最快的領域。推動該領域成長的關鍵因素之一是新型生物標記開發研究的擴展。
  • 就 2023 年的收益佔有率而言，診斷細分市場佔據主導地位。高效且有效的腫瘤測試特異性癌症生物標記的開發進展以及政府舉措的增加可能會支持該領域的成長。
  • 個人化醫療領域是預測期內成長最快的領域。
  • 成像技術領域因其在生物標記發現和診斷方面的高性能、準確性和廣泛適用性，在 2023 年佔據了市場佔有率。
  • 北美在癌症生物標記市場佔據主導地位，2023 年銷售佔有率為 43.84%。這一優勢是由於存在大量專門研究癌症生物標記的市場參與企業，以及美國政府在促進創新的研發方面的大量投資。
  • 預計亞太地區癌症生物標記市場在預測期內將以 14.3% 的複合年成長率成長最快。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章癌症生物標記市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 癌症生物標記市場分析工具
    • 波特的分析
    • PESTEL分析

第4章癌症生物標記市場：按類型估計和趨勢分析

  • 細分儀表板
  • 癌症生物標記市場：類型變異分析，2023 年和 2030 年
  • 乳癌
  • 攝護腺癌
  • 大腸直腸癌
  • 子宮頸癌
  • 肝癌
  • 肺癌
  • 其他

第5章癌症生物標記市場：生物分子的估計與趨勢分析

  • 細分儀表板
  • 癌症生物標記市場：生物分子變異分析，2023 年和 2030 年
  • 基因生物標記
  • 表觀遺傳學生物標記物
  • 代謝生物標記
  • 蛋白質體生物標記
  • 其他

第6章癌症生物標記市場：按應用、估計和趨勢分析

  • 細分儀表板
  • 癌症生物標記市場：2023 年和 2030 年應用變化分析
  • 藥物發現與開發
  • 診斷
  • 個人化醫療
  • 其他

第7章癌症生物標記市場：技術估計和趨勢分析

  • 細分儀表板
  • 癌症生物標記市場：2023 年和 2030 年技術變化分析
  • 成像技術
  • 體學

第8章癌症生物標記市場：按地區估計和趨勢分析

  • 2023 年和 2030 年癌症生物標記市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Abbott
    • QIAGEN
    • Thermo Fisher Scientific Inc
    • Affymetrix Inc
    • Illumina, Inc.
    • Agilent Technologies
    • F. Hoffmann-La Roche AG
    • Merck &Co. Inc
    • Hologic, Inc
    • Sino Biological Inc
簡介目錄
Product Code: GVR-1-68038-862-6

Cancer Biomarkers Market Growth & Trends:

The global cancer biomarkers market size is expected to reach a value of USD 69.76 billion by 2030 and is anticipated to expand at a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing initiatives for development of drugs targeting novel cancer biomarkers coupled with the introduction of technologically advanced companion diagnostic kits is estimated to provide the market with high growth potential. Increasing awareness about personalized medicines amongst patients is further anticipated to boost adoption of cancer biomarkers.

In addition, presence of favorable government initiatives for the development of novel cancer diagnostic techniques is a key factor for market growth. For instance, the National Cancer Institute (NCI) provides funding to more than 8 research areas pertaining to cancer biomarker development. Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health are some of the organizations providing funding for biomarker research.

People with high alcohol consumption, tobacco usage, unhealthy food habits, and sedentary lifestyle are reported to be 80% more at risk of developing cancer as compared to other individuals. Infections such as Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori are also been studied to be related in cancer development.

Cancer Biomarkers Market Report Highlights:

  • The breast cancer segment held a significant market share in terms of revenue in 2023 and it is also expected to be the witness the fastest CAGR over the forecast period.
  • The others segment held a notable share in 2023 pertaining to the increased research on rare cancers, advancements in genomics and proteomics, the rising incidence of cancers such as pancreatic and ovarian, and the growing demand for personalized medicine.
  • The genetic biomarkers segment dominated the market in terms of revenue share in 2023. Genetic biomarkers are crucial in the cancer biomarkers market due to several driving factors.
  • The epigenetics segment is expected to be the fastest growing segment over the forecast period. One of the key drivers boosting the growth of the segment is the growing research for the development of novel biomarkers.
  • The diagnostics segment dominated the market in terms of revenue share in 2023. Factors such as the growing development of cancer biomarkers based on oncology tests that are highly efficient and effective and growing government initiatives may drive the segment's growth.
  • The personalized medicine segment is the fastest growing segment during the forecast period.
  • The imaging technologies segment dominated the market share in 2023 due to its high-throughput nature, accuracy, and broad applicability in biomarker discovery and diagnosis.
  • North America dominated the cancer biomarkers market with revenue share of 43.84% in 2023. This dominance is due to the presence of numerous market players dedicated to cancer biomarkers and substantial investments by the U.S. government in research and development efforts, which foster innovation.
  • Asia Pacific cancer biomarkers market is anticipated to witness the fastest growth at a CAGR of 14.3% over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Biomarkers Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Cancer Biomarkers Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Cancer Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cancer Biomarkers Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Breast Cancer
    • 4.3.1. Breast Cancer Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Prostate Cancer
    • 4.4.1. Prostate Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Colorectal Cancer
    • 4.5.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Cervical Cancer
    • 4.6.1. Cervical Cancer Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Liver Cancer
    • 4.7.1. Liver Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Lung Cancer
    • 4.8.1. Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Biomarkers Market: Biomolecule Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cancer Biomarkers Market: Biomolecule Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Genetic Biomarkers
    • 5.3.1. Genetic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Epigenetic Biomarkers
    • 5.4.1. Epigenetic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Metabolic Biomarkers
    • 5.5.1. Metabolic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Proteomic Biomarkers
    • 5.6.1. Proteomic Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Biomarkers Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Cancer Biomarkers Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Drug Discovery and Development
    • 6.3.1. Drug Discovery and Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Diagnostics
    • 6.4.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Personalized Medicine
    • 6.5.1. Personalized Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cancer Biomarkers Market: Technology Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Cancer Biomarkers Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Imaging Technology
    • 7.3.1. Imaging Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. OMICS
    • 7.4.1. OMICS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Cancer Biomarkers Market: Regional Estimates & Trend Analysis

  • 8.1. Cancer Biomarkers Market Share, By Region, 2023 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Norway Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. China Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Australia Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. South Korea
      • 8.4.7.1. South Korea Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. UAE Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Cancer Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Abbott
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. QIAGEN
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. Thermo Fisher Scientific Inc
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Affymetrix Inc
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Illumina, Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Agilent Technologies
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. F. Hoffmann-La Roche AG
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Merck & Co. Inc
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Hologic, Inc
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Sino Biological Inc
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives